Interesting data suggesting the Pfizer/BioNTech works best as a three-dose vaccine. Initial 3-dose antibody titres being so much higher than 2-dose ones makes a stronger case than I had anticipated for administrating boosters outside just the most at-risk demographies. https://t.co/yt2mFm27Hx

— Prof Francois Balloux (@BallouxFrancois) October 21, 2021